Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience

Figures & data

Table 1. Information about the patients and medication of ustekinumab.

Parameters	Results
Disease duration	15.64 ± 9.95 years (min 2, max 53)
Duration of medication	23.13 ± 15.93 months in total cases (min 7, max 72) 21.9 ± 13.09 in females 23.88 ± 17.52 in males
Naive cases	100 (73.52%) total 39 (75%) female 61 (72.61%) male
Non naive cases	36 (26.47%) total 13 (25%) female 23 (27.38%) male

Table 2. Information about PASI 75-90-100 responses of all the patients and female and male patients Separately.

Parameters	PASI 75			PASI 90			PASI 100
	Total	Female	Male	Total	Female	Male	Total	Female	Male
Total number	41	12	29	69	24	45	64	22	42
Missed cases	95	40	55	67	28	39	72	30	42
Mean week	5.32	5.08	5.41	6.19	7.83	5.31	8.86	9	8.79
Std.	3.588	2.811	3.905	5.862	8.766	3.267	6.650	6.495	6.806
Minimum (week)	1	1	1	1	1	1	1	4	1
Maximum (week)	16	9	16	36	36	12	36	26	36

Abbreviations: PASI, psoriasis area and severity index.

Table 3. Comparison between male and female cases about time to reach PASI 75-90-100 responses.

PASI	Gender	Number	Week (mean ± std)	p
PASI 75	M	29	5.41 ± 3.9	0.92
	F	12	5.08 ± 2.8
PASI 90	M	45	5.31 ± 3.2	0.68
	F	24	7.83 ± 8.7
PASI 100	M	42	8.79 ± 6.8	1
	F	22	9 ± 6.4

PASI: psoriasis area and severity index; M: male; F: female. ‘Week’ means the duration of receiving PASI75-90-100 responses.

Table 4. Comparision between naive and non naive cases about PASI 75-90-100 responses.

Cases	Naïve (total)	Non naïve (total)	p	Naïve (female)	Non naïve (female)	p	Naïve (male)	Non naïve (male)	p
PASI 75
Response [n (%)]	77 (56.6%)	29 (21.3%)	.4	26 (50%)	10 (19.2%)	.14	51 (60.7%)	19 (22.6%)	1
Not response [n (%)]	23 (16.9 %)	7 (5.1%)		13 (25%)	3 (2.2%)		10 (19.2%)	4 (4.8%)
PASI 90
Response [n (%)]	48 (35.3%)	21 (15.4%)	.33	16 (30.8%)	8 (15.4%)	.22	32 (38%)	29 (34.5%)	.8
Not response [n (%)]	52 (38.2%)	15 (11%)		23 (44.3%)	5 (9.6%)		13 (15.5%)	10 (11.9%)
PASI 100
Response [n (%)]	47 (34.6%)	17 (12.5%)	1	16 (30.8%)	6 (11.5%)	.75	31 (37%)	11 (13%)	1
Not response [n (%)]	53 (39%)	19 (14%)		23 (44.2%)	7 (13.5%)		30 (35.7%)	12 (14.3%)

PASI: psoriasis area and severity index. p < .05 (*) statically significant correlation.

Data availability statement

Data has been received in İzmir Tepecik Training and Research Hospital.